Citation
Moutaharrik, S, et al. "In Vitro and in Vivo Evaluation of a pH-, Microbiota- and Time-based Oral Delivery Platform for Colonic Release." European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, vol. 183, 2023, pp. 13-23.
Moutaharrik S, Maroni A, Neut C, et al. In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release. Eur J Pharm Biopharm. 2023;183:13-23.
Moutaharrik, S., Maroni, A., Neut, C., Dubuquoy, C., Dubuquoy, L., Foppoli, A., Cerea, M., Palugan, L., Siepmann, F., Siepmann, J., & Gazzaniga, A. (2023). In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, 183, 13-23. https://doi.org/10.1016/j.ejpb.2022.12.013
Moutaharrik S, et al. In Vitro and in Vivo Evaluation of a pH-, Microbiota- and Time-based Oral Delivery Platform for Colonic Release. Eur J Pharm Biopharm. 2023;183:13-23. PubMed PMID: 36563887.
TY - JOUR
T1 - In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release.
AU - Moutaharrik,S,
AU - Maroni,A,
AU - Neut,C,
AU - Dubuquoy,C,
AU - Dubuquoy,L,
AU - Foppoli,A,
AU - Cerea,M,
AU - Palugan,L,
AU - Siepmann,F,
AU - Siepmann,J,
AU - Gazzaniga,A,
Y1 - 2022/12/20/
PY - 2022/10/13/received
PY - 2022/12/10/revised
PY - 2022/12/18/accepted
PY - 2022/12/24/pubmed
PY - 2022/12/24/medline
PY - 2022/12/23/entrez
KW - 5-aminosalicylic acid
KW - Chitosan
KW - Combined time-, pH- and microbiota-dependent approach
KW - Eudragit® S
KW - Hydroxypropyl cellulose
KW - Hydroxypropyl methylcellulose
KW - Oral colon delivery
KW - Pectin
KW - Spray-coating
SP - 13
EP - 23
JF - European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JO - Eur J Pharm Biopharm
VL - 183
N2 - Several formulation strategies have been proposed for oral colon delivery, particularly for the therapy of inflammatory bowel disease (IBD). However, targeting the large intestine remains a challenging goal. The aim of this study was to develop and evaluate a novel type of drug delivery system, which is based on multiple drug release triggers for reliable performance. The system consists of: (i) a drug core, (ii) an inner swellable low-viscosity hydroxypropyl methylcellulose (HPMC) layer, and (iii) an outer film coating based on a Eudragit® S:high-methoxyl (HM) pectin (7:3 w/w) blend, optionally containing chitosan. Convex immediate release tablets (2 or 4 mm in diameter) containing paracetamol or 5-aminosalicylic acid (5-ASA) were coated in a fluid bed. The double-coated tablets exhibited pulsatile release profiles when changing the release medium from 0.1 N HCl to phosphate buffer pH 7.4. Also, drug release was faster in simulated colonic fluid (SCF) in the presence of fecal bacteria from IBD patients compared to control culture medium from tablets with outer Eudragit® S: HM pectin: chitosan coatings. The latter systems showed promising results in the control of the progression of colitis and alteration of the microbiota in a preliminary rat study.
SN - 1873-3441
UR - https://www.unboundmedicine.com/medline/citation/36563887/In_vitro_and_in_vivo_evaluation_of_a_pH__microbiota__and_time_based_oral_delivery_platform_for_colonic_release_
DB - PRIME
DP - Unbound Medicine
ER -